about
Advances in rheumatology: new targeted therapeuticsWhat makes psoriatic and rheumatoid arthritis so different?The role of p38 MAPK in the aetiopathogenesis of psoriasis and psoriatic arthritisOptimal management of dactylitis in patients with psoriatic arthritisEarly biomarkers of joint damage in rheumatoid and psoriatic arthritisProgressive and concordant expression of PKC-eta and iNOS phenotypes in monocytes from patients with rheumatoid arthritis: association with disease severity.Reactive oxygen species in tumor necrosis factor-alpha-activated primary human keratinocytes: implications for psoriasis and inflammatory skin disease.Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progressionMacrophage migration inhibitory factor (MIF) promoter polymorphisms (-794 CATT5-8 and -173 G>C): association with MIF and TNFα in psoriatic arthritis.Single administration of lesion-limited high-dose (TURBO) ultraviolet B using the excimer laser: clinical clearing in association with apoptosis of epidermal and dermal T cell subsets in psoriasis.Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis.Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis.Effects of nerve growth factor (NGF) on blood vessels area and expression of the angiogenic factors VEGF and TGFbeta1 in the rat ovaryBone mineral density and body composition in postmenopausal women with psoriasis and psoriatic arthritis.Gene Expression Profiling in Peripheral Blood Cells and Synovial Membranes of Patients with Psoriatic ArthritisAnkylosing spondylitis: recent breakthroughs in diagnosis and treatmentImmune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolutionThe need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?Tumor necrosis factor as a therapeutic target of rheumatologic disease.Infliximab (Remicade) in the treatment of psoriatic arthritis.Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).Genetics of susceptibility and treatment response in psoriatic arthritis.Management of psoriasis in Africa and the Middle East: a review of current opinion, practice and opportunities for improvement.New insights into the role of T cells in pathogenesis of psoriasis and psoriatic arthritis.Angiogenesis Dysregulation in Psoriatic Arthritis: Molecular Mechanisms.Angiogenic and inflammatory properties of psoriatic arthritis.Functional role of IL-22 in psoriatic arthritis.Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-α blockade in the knee joint.The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year.Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease.The beneficial effect of total glucosides of paeony on psoriatic arthritis links to circulating Tregs and Th1 cell function.Psoriatic nail involvement and its relationship with distal interphalangeal joint disease.The Therapeutic Potential and Molecular Mechanism of Isoflavone Extract against Psoriasis.Non-invasive In Vivo Fluorescence Optical Imaging of Inflammatory MMP Activity Using an Activatable Fluorescent Imaging Agent.
P2860
Q21093257-93D9DCDA-B13F-4B88-9D8A-AFC71D6C2B56Q26778261-B1C3E896-1C86-4454-BB07-3FBA20650C38Q26821943-EDADFEB4-3339-4EFC-BBE8-3412176E893CQ28072557-5C4A8900-EA2C-41A3-8C42-1FBD161659AAQ28083506-E1D25613-D867-4271-9A62-AB540425AEF7Q33270013-303B98F2-7530-4FD9-8285-90A06C7829B0Q33915587-5C8213E1-6A81-492F-AB36-BBA219BCCFFDQ34154244-03522B39-FE05-46A5-9714-A410301464DAQ34414970-0E0BF5BF-6D0B-4618-9A4C-DEF568A1D914Q34466675-1CE9CB75-CD50-48AD-B223-152529817BA5Q34572305-17ABD3E9-5C01-4739-AAFD-589D5CA97FD2Q34896320-1368663F-56F7-4F77-B862-B6E8CD996B20Q35173690-262E99B5-CF07-4025-AD22-7F291596EA4FQ35620308-34CDE0BE-F017-4017-98AE-245D22CF4D0DQ35667354-021E7851-86AC-41FF-8682-E635C595BBB0Q36143588-A8EF00D3-736E-4B4F-9AA9-050E2212C580Q36778450-4291D5E8-D5AB-4B6E-A6A5-8CA42596F50EQ36790324-0E71F58C-4FCC-4E48-9183-898C91D0D243Q37008829-05BF8FE0-E01F-448B-9007-7236CA4A2CA4Q37116853-299799D2-E1BA-4E09-B2E9-1FCC54BEFAFCQ37465550-9A24429C-F621-4DF8-8E85-E68C06CE51DEQ37953810-D53AD255-95AC-4D20-BE70-CA45D424CD5FQ37961072-2EC21848-EEE8-45E4-B771-6666535FCFC1Q38799600-CD488810-B300-4374-BD4B-C6E387E4A37FQ41208827-4E036278-AE50-404D-AD23-85A9BFD5FB4DQ42156810-20B3DD77-0088-4ABF-B634-E480FE3B9908Q42326323-CDEAC8FD-81B7-47CF-A5D0-F7C9739853B6Q42420342-4704831A-0FB8-4C31-A05B-699949B3CB4FQ42955715-5CE7DC78-427E-4619-990D-C84C159CA660Q44204800-7FCEBBCA-F721-41C2-87BF-3E12712029A0Q51050640-52CAE357-A907-4248-9271-A1D8C78D18ECQ51725167-FC2E56B5-D597-437C-96B6-1AFE851565A5Q52573359-52AC83E8-6177-49AA-8E1D-AEB5DC71BE52Q52868140-ADD1A90B-64BD-4024-892E-466B957864DC
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Immunopathology of psoriasis and psoriatic arthritis
@ast
Immunopathology of psoriasis and psoriatic arthritis
@en
type
label
Immunopathology of psoriasis and psoriatic arthritis
@ast
Immunopathology of psoriasis and psoriatic arthritis
@en
prefLabel
Immunopathology of psoriasis and psoriatic arthritis
@ast
Immunopathology of psoriasis and psoriatic arthritis
@en
P2860
P356
P1476
Immunopathology of psoriasis and psoriatic arthritis
@en
P2093
FitzGerald O
P2860
P304
P356
10.1136/ARD.2004.031740
P407
P478
64 Suppl 2
P577
2005-03-01T00:00:00Z